Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA:688192)
China flag China · Delayed Price · Currency is CNY
55.45
-2.11 (-3.67%)
At close: Apr 9, 2026

SHA:688192 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
801.14359.991.29-10.29
801.14359.991.29-10.29
Revenue Growth (YoY)
122.60%294.25%---62.95%
Cost of Revenue
34.2311.847.663.6512.93
Gross Profit
766.91348.0683.63-3.65-2.65
Selling, General & Admin
730.95598.78437.55128.4487.95
Research & Development
855.61721.16801.15660.87583.67
Other Operating Expenses
-59.32-2.1-0.27-0.390.1
Operating Expenses
1,5271,3181,239788.9671.73
Operating Income
-760.33-969.66-1,155-792.55-674.37
Interest Expense
--22.75-7.57-4.34-3.07
Interest & Investment Income
-2.243.642.533.65
Currency Exchange Gain (Loss)
--2.45-1.4510.1-6.45
Other Non Operating Income (Expenses)
-32.13-0.07-0.04-0.03-0.08
EBT Excluding Unusual Items
-792.45-992.69-1,161-784.3-680.32
Gain (Loss) on Sale of Investments
25.3314.4522.5242.160.97
Gain (Loss) on Sale of Assets
0--0.010.02-
Other Unusual Items
-38.5930.56.399.47
Pretax Income
-767.13-939.65-1,108-735.74-669.88
Income Tax Expense
1.3900.10.26-
Earnings From Continuing Operations
-768.52-939.66-1,108-736-669.88
Minority Interest in Earnings
4.4793.7---
Net Income
-764.05-845.96-1,108-736-669.88
Net Income to Common
-764.05-845.96-1,108-736-669.88
Shares Outstanding (Basic)
447415407404360
Shares Outstanding (Diluted)
447415407404360
Shares Change (YoY)
7.75%1.83%0.70%12.29%0.07%
EPS (Basic)
-1.71-2.04-2.72-1.82-1.86
EPS (Diluted)
-1.71-2.04-2.72-1.82-1.86
Free Cash Flow
-758.79-788.1-1,000-677.15-501.26
Free Cash Flow Per Share
-1.70-1.90-2.46-1.67-1.39
Gross Margin
95.73%96.71%91.61%--25.72%
Operating Margin
-94.91%-269.43%-1265.43%--6556.55%
Profit Margin
-95.37%-235.05%-1213.42%--6512.85%
Free Cash Flow Margin
-94.72%-218.98%-1095.44%--4873.51%
EBITDA
-715.03-930.08-1,114-753.85-636.97
EBITDA Margin
-89.25%-258.43%---
D&A For EBITDA
45.339.5840.9438.737.4
EBIT
-760.33-969.66-1,155-792.55-674.37
EBIT Margin
-94.91%-269.43%---
Revenue as Reported
-359.991.29-10.29
Advertising Expenses
---1.94-
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.